J&J's experimental psoriasis drug shows promise against Bristol's treatment
Johnson & Johnson said its experimental psoriasis drug has shown superior skin clearance compared to Bristol Myers Squibb's Sotyktu in two head-to-head trials.
You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.